# UK Human Genetics Market > UK Human Genetics Market Research Report By Application (Wellness & E-Commerce, Preventive Medicine, Diagnostic & Treatment) andBy Test (NIPT, Carrier Testing, Pharmacogenomic Testing, Karyotype Testing, Thrombophilia Testing, Septin 9 Biomarker Testing, NGS, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.8% - **2024:** $ 1,589.45 Million - **2025:** $ 1,761.11 Million - **2035:** $ 4,912.15 Million - **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Agilent Technologies (US), QIAGEN (DE), Myriad Genetics (US), BGI Genomics (CN), Genomatix (DE), Fulgent Genetics (US) **Report ID:** MRFR/LS/47560-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-human-genetics-market-49310 --- ## Market Summary ## **UK Human Genetics Market Overview** As per MRFR analysis, the UK Human Genetics Market Size was estimated at $1.43 billion in 2023. The UK Human Genetics Market is expected to grow from $1.59 billion in 2024 to $4.72 billion by 2035. The UK Human Genetics Market CAGR (growth rate) is expected to be around 10.404% during the forecast period (2025 - 2035). ### **Key UK Human Genetics Market Trends Highlighted** Growing awareness of genetic problems, increased investment in personalized medicine, and technological improvements are all driving important developments in the UK human genetics market. Early diagnosis and focused treatments are becoming more affordable and accessible for patients in the UK thanks to the development of genome sequencing technologies. Additionally, the UK government has provided funding through initiatives like the 100,000 Genomes Project, which has sparked research in genetic testing and precision medicine, and other policies meant to promote genomics innovation. The aging of the population and the increasing prevalence of genetic illnesses are significant factors driving this market, as they generate a need for genetic testing and counseling services. The development of gene therapies that target certain disorders and the growth of genetic testing services are two opportunities to be investigated in the UK human genetics market. Additionally, there is a rising movement to incorporate genomic data into electronic health records, which can improve patient care by giving medical practitioners access to thorough genetic data. In the UK, genetic screening initiatives are being used more frequently as part of the NHS's effort to enhance patient outcomes. Recent trends also indicate that industry, academia, and healthcare providers are working together more and more to promote human genetics research and therapeutic applications. Proactively addressing the ethical issues of genetic testing and data privacy helps to increase public trust and motivate more people to take part in genetic research. All things considered, the UK is well-positioned for expansion in the field of human genetics thanks to its distinctive healthcare system and dedication to innovation. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **UK Human Genetics Market Drivers** ### **Increasing Prevalence of Genetic Disorders** The UK has seen a significant increase in the prevalence of genetic disorders, which is driving the demand for human genetics services and solutions. According to the National Health Service (NHS), approximately 1 in 25 people in the UK are affected by rare genetic disorders, which translates to around 1.2 million individuals. This alarming statistic, coupled with advancements in genetic testing and Research and Development within the field, has created an urgent need for innovative solutions. Major healthcare organizations such as Genomics England are at the forefront of this development, using genomic data to create targeted therapies and early diagnosis tools. This surge in the need for genetic solutions is a key driver of growth in the UK Human Genetics Market, with implications for research funding and healthcare infrastructure, as the government aims to integrate genomic medicine into routine clinical practice by embedding it within the NHS system by 2025. ### **Government Initiatives and Funding** The UK government has placed a strong emphasis on developing the biotechnology and genetics sectors as part of its long-term industrial strategy. Notably, the UK has committed to investing substantial amounts into genomics research and infrastructure. The UK government announced an investment of 200 million GBP to advance the 100,000 Genomes Project, which aims to sequence genomes for patients with rare diseases and cancer. This strategic direction is leading to an influx of capital into the UK Human Genetics Market, making it an attractive area for both domestic and international investors. Encouragement from public funding bodies and the ability to access grants are driving many entities toward innovation in genetic healthcare solutions. ### **Technological Advances in Genetic Testing** The evolution of genomic sequencing technologies has made genetic testing more affordable and accessible in the UK, thereby driving market growth. Technologies like Next-Generation Sequencing (NGS) have significantly reduced the cost and time required to conduct genetic tests. The price of whole-genome sequencing dropped by more than 99% in the last decade, allowing broader patient access and the feasibility of implementing comprehensive genetic testing within the NHS framework. Companies like Illumina and Oxford Nanopore Technologies are pioneers in this space, offering commercial solutions that facilitate genetic diagnostics. These advances empower healthcare professionals to diagnose and treat genetic conditions more effectively, thus catalyzing growth within the UK Human Genetics Market. ### **Rising Burden of Chronic Diseases** Chronic diseases, often with a genetic component, have become a significant concern in the UK healthcare landscape. It is estimated that 20% of the population in the UK live with chronic health conditions. Conditions such as heart disease, diabetes, and certain cancers often exhibit genetic predispositions. According to Public Health England, around 250,000 people are diagnosed with cancer each year, underscoring the urgent need for epidemiological studies linking genetics to these diseases. This drive toward understanding the genetic underpinning of chronic conditions has prompted healthcare providers and research institutions to engage more deeply in genomic studies. Organizations like Cancer Research UK are actively involved in such research, leading to increased demand for genetic diagnostics and personalized treatments in the UK Human Genetics Market. ## **UK Human Genetics Market Segment Insights** ### **Human Genetics Market Application Insights** The Application segment of the UK [Human Genetics Market](../../../reports/human-genetics-market-714) plays a vital role in enhancing personalized healthcare solutions and is experiencing significant growth across various categories. The importance of Wellness and E-Commerce emerges from the increasing public interest in genetic information that aids in lifestyle management and preventive health strategies. This area is driven by consumers who seek tailored health recommendations based on their genetic profiles. Preventive Medicine stands out in this market by focusing on early detection and risk assessment, enabling healthcare professionals to provide proactive solutions tailored to individual genetic predispositions. This approach is increasingly crucial as the UK healthcare system transitions toward preventive care rather than reactive treatment. In addition, Diagnostic and Treatment practices form a cornerstone of the Application landscape by utilizing genetic information to guide precision medicine and treatment strategies, ultimately improving patient outcomes. With advancements in genome sequencing and bioinformatics, these practices can identify genetic markers associated with various diseases, enhancing diagnosis accuracy and effective treatment plan development. This drives the market growth as healthcare providers and patients alike recognize the value of genetic insights in creating targeted therapies. Overall, as innovation continues to flourish within these realms, the Application segment of the UK Human Genetics Market is set to broaden the horizons of what is possible in genetics-based healthcare, addressing both individual and public health needs while responding to ongoing trends in consumer health awareness, technology, and collaborative healthcare practices. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Human Genetics Market Test Insights** The UK Human Genetics Market, particularly in the Test segment, has seen considerable evolution, reflecting advancements in technology and an increased understanding of genetic conditions. Among the key areas of focus, Non-Invasive Prenatal Testing (NIPT) has gained traction due to increased demand for safer prenatal screening options, offering high accuracy without the risks associated with invasive testing. Carrier Testing plays a crucial role in identifying genetic disorders in potential parents, which helps inform reproductive choices, thus enhancing public health outcomes. Pharmacogenomic Testing, essential for personalized medicine, allows healthcare providers to tailor medication plans based on an individual's genetic makeup, promoting efficacy and minimizing adverse effects. Karyotype Testing has maintained significance for chromosomal analysis, aiding in diagnosing genetic disorders through a detailed evaluation of oddities in karyotypes. Thrombophilia Testing identifies inherited blood clotting disorders, which is critical for preventive healthcare strategies. The Septin 9 Biomarker Testing is noteworthy for its applications in colorectal cancer screening, providing important insights for early intervention. Next-generation sequencing (NGS) dominates in providing comprehensive data on genetic variations, enabling a deeper understanding of rare disorders and genetic predispositions. Collectively, these offerings within the Test segment greatly contribute to personalized healthcare in the UK, fulfilling an ongoing need for innovative diagnostic solutions and fostering better patient outcomes. ## **UK Human Genetics Market Key Players and Competitive Insights** The UK Human Genetics Market is a rapidly evolving sector characterized by significant advancements in genomics, diagnostics, and therapeutics. Its competitive landscape is shaped by a multitude of players, including biotechnology firms, pharmaceutical companies, and research institutions dedicated to enhancing human health through genetic insights. With an increasing focus on personalized medicine and genome sequencing, the market has witnessed substantial investments in research and development, leading to innovative technologies and solutions. This growing emphasis on genetic research and application has spurred competition among key industry participants, resulting in a vibrant marketplace that addresses the demands for more effective treatments and precision in healthcare. As the market expands, understanding the strengths, weaknesses, and strategic positioning of key competitors becomes essential for stakeholders aiming to navigate the complex dynamics of the UK Human Genetics Market. Illumina stands out prominently within the UK Human Genetics Market for its pioneering advancements in DNA sequencing and genomic analysis technologies. The company has established a strong presence through its innovative platforms and systems that facilitate high-throughput sequencing, enabling researchers and clinicians to conduct extensive genetic studies. Illumina's strengths lie in its robust portfolio of sequencing instruments, reagents, and informatics solutions, which are integral to both academic research and clinical diagnostics. The company's commitment to continual innovation and enhancing the accessibility of genomic data has solidified its position as a leader in the field, fueling collaborations with various universities, hospitals, and research organizations across the UK. Illumina's strategic focus on technological enhancements, coupled with its deep understanding of the UK healthcare landscape, further establishes its competitive edge in this flourishing market. AB Sciex also plays a crucial role in the UK Human Genetics Market, primarily through its innovative solutions in mass spectrometry and analytical chemistry. The company specializes in providing high-quality analytical systems and methodologies that facilitate the study of complex biological samples, thereby advancing the understanding of human genetics. AB Sciex's strengths are evident in its cutting-edge instruments and reagents designed for precise quantification and characterization of biomolecules, enabling researchers to make significant contributions in areas such as biomarker discovery and genomics. The company's presence in the UK is further amplified by strategic partnerships and collaborations aimed at enhancing its product offerings and expanding its reach. AB Sciex has also engaged in significant mergers and acquisitions to bolster its market position, allowing it to integrate advanced technologies and broaden its service capabilities. This continuous drive for enhancement and collaboration contributes to AB Sciex’s prominent standing in the UK Human Genetics Market, as it offers indispensable tools and solutions that cater to the evolving needs of genetic research and diagnostics. ### Key Companies in the UK Human Genetics Market Include - Illumina - AB Sciex - LGC Group - QIAGEN - Myriad Genetics - Regeneron Pharmaceuticals - Synthace - GeneVue - PerkinElmer - **[Thermo Fisher Scientific](https://www.thermofisher.com/in/en/home/life-science/sequencing/sequencing-applications/complex-disease/human-genetics-research.html)** - Genomics England - Ginkgo Bioworks - 23andMe - Merck KGaA - Oxford Nanopore Technologies ### **UK Human Genetics Market Developments** In recent months, the UK Human Genetics Market has witnessed significant progress, particularly in genomic research and testing. Companies such as Illumina and QIAGEN are leading advancements in next-generation sequencing technologies, contributing to the enhancement of precision medicine in the UK healthcare sector. Recently, in September 2023, Illumina announced an agreement with Genomics England to collaborate on expanding genetic testing capabilities within the National Health Service, which is expected to improve accessibility to genomic diagnostics. Additionally, Regeneron Pharmaceuticals reported new findings in gene therapy that could potentially transform treatments for rare diseases, further illustrating the innovation landscape in the UK. In terms of mergers, in August 2023, Myriad Genetics acquired a portfolio of diagnostic tests from a competing firm, broadening its capabilities in hereditary cancer testing within the UK. In the past few years, significant investments have been made, notably by Oxford Nanopore Technologies, which raised substantial funding in early 2022 to drive product development and market expansion. This flourishing market appears poised for further growth, driven by advancements in genetic research and strategic collaborations among key players. ## **UK Human Genetics Market Segmentation Insights** ### **Human Genetics Market Application Outlook** - Wellness & E-Commerce - Preventive Medicine - Diagnostic & Treatment ### **Human Genetics Market Test Outlook** - NIPT - Carrier Testing - Pharmacogenomic Testing - Karyotype Testing - Thrombophilia Testing - Septin 9 Biomarker Testing - NGS ## Market Drivers ### Growing Demand for Personalized Medicine The human genetics market is experiencing a notable shift towards personalized medicine, driven by an increasing demand for tailored healthcare solutions. Patients and healthcare providers are seeking treatments that are specifically designed to meet individual genetic profiles. This trend is reflected in the rising number of genetic tests being conducted, with estimates suggesting that the market for genetic testing in the UK could reach £1.5 billion by 2026. As healthcare systems increasingly adopt precision medicine approaches, the human genetics market is likely to expand, offering innovative therapies and interventions that align with patients' unique genetic makeups. ### Increased Public Awareness and Education Public awareness regarding genetic health and its implications is on the rise, significantly impacting the human genetics market. Educational campaigns and initiatives by health organizations are informing the public about the benefits of genetic testing and the potential for early disease detection. Surveys indicate that approximately 60% of the UK population is now aware of genetic testing options available to them. This heightened awareness is likely to drive demand for genetic services, as individuals seek proactive measures to manage their health, thereby contributing to the growth of the human genetics market. ### Regulatory Support for Genetic Innovations The regulatory landscape in the UK is evolving to support advancements in the human genetics market. Regulatory bodies are increasingly recognizing the importance of genetic research and are streamlining approval processes for genetic tests and therapies. Recent changes in regulations have reduced the time required for new genetic tests to reach the market, fostering innovation. This supportive environment is expected to encourage investment in genetic research and development, potentially leading to a market growth rate of 10% annually over the next five years, as companies seek to capitalize on new opportunities within the human genetics market. ### Collaboration Between Academia and Industry Collaboration between academic institutions and industry players is becoming a driving force in the human genetics market. Partnerships are facilitating the translation of research findings into practical applications, enhancing the development of genetic tests and therapies. The UK is home to numerous research institutions that are actively collaborating with biotech companies, leading to the establishment of innovative genetic solutions. This synergy is likely to accelerate advancements in the field, with projections indicating that collaborative efforts could result in a 15% increase in the number of genetic products launched in the next few years, thereby bolstering the human genetics market. ### Technological Innovations in Genetic Research Technological advancements are playing a pivotal role in the evolution of the human genetics market. Innovations such as next-generation sequencing (NGS) and CRISPR gene editing are enhancing the capabilities of genetic research, enabling more accurate and efficient analysis of genetic information. The UK has seen a surge in research funding, with government initiatives allocating over £300 million to support genetic research projects. These technological breakthroughs not only facilitate the discovery of new genetic markers but also improve the development of targeted therapies, thereby propelling the human genetics market forward. ## Future Outlook The [Human Genetics Market](https://www.marketresearchfuture.com/reports/human-genetics-market-714) is projected to grow at a 10.8% CAGR from 2025 to 2035, driven by advancements in genomic technologies, personalized medicine, and increasing healthcare investments. **New opportunities:** - Development of AI-driven genetic analysis platforms - Expansion of direct-to-consumer genetic testing services - Partnerships with biotech firms for innovative gene therapies By 2035, the human genetics market is expected to be robust, reflecting substantial growth and innovation. ## Segment Insights ### By Application: Wellness & E-Commerce (Largest) vs. Preventive Medicine (Fastest-Growing) In the UK human genetics market, the application segment shows a varied distribution among key values. Wellness & E-Commerce holds the largest share, driven by the rising trend of personalized health solutions. Preventive Medicine, while smaller, is rapidly gaining traction as consumers become more proactive about their health, looking to genetic insights to prevent potential health issues. Growth trends within this segment are influenced by increasing consumer awareness and technological advancements. The surge in telehealth services, coupled with the demand for home-based wellness solutions, has boosted the Wellness & E-Commerce sector. Preventive Medicine is experiencing growth due to heightened focus on proactive health measures facilitated by genetic testing, showcasing a shift towards early diagnosis and intervention strategies. Wellness & E-Commerce (Dominant) vs. Preventive Medicine (Emerging) The Wellness & E-Commerce segment serves as the dominant force in the UK human genetics market, capitalizing on a growing consumer base interested in personalized health and lifestyle products. It encompasses a wide range of services from direct-to-consumer genetic tests to wellness app integrations. On the other hand, Preventive Medicine is emerging, focusing on leveraging genetic data to avert health risks. This sector is defined by innovations in predictive analytics and is gradually reshaping patient care paradigms by emphasizing early detection and personalized health strategies. Both segments exhibit unique characteristics that cater to distinct consumer needs, indicating a dynamic and evolving market landscape. ### By Test: NIPT (Largest) vs. Carrier Testing (Fastest-Growing) In the UK human genetics market, the distribution of market share among different testing segments reveals that NIPT holds the largest share, capitalizing on its non-invasive nature and rising endorsement by healthcare providers. Carrier Testing follows, making significant contributions due to increasing awareness of genetic disorders and the precision of results it provides to prospective parents. Each of these segments plays a critical role in the overall landscape, catering to specific needs and prompting advancements across the testing sphere. Growth trends indicate that while NIPT continues to dominate, Carrier Testing is emerging rapidly, driven by a rise in personalized healthcare and genetic counseling. The demand for tests that cater to inherited diseases is surging, encouraging investments and innovation in technologies that enhance the accuracy and efficiency of these tests. Moreover, advancements in genetic research and processes contribute to the rapid adoption of these testing services, redefining the future of prenatal and pre-conception healthcare. NIPT (Dominant) vs. Carrier Testing (Emerging) NIPT is regarded as the dominant segment in the UK human genetics market, characterized by its ability to detect fetal genetic issues through maternal blood samples. This method is praised for its accuracy, safety, and non-invasiveness, making it highly favorable among patients and healthcare providers alike. In contrast, Carrier Testing is an emerging segment, gaining traction as an essential tool for couples planning families, enabling them to understand their genetic risks. Both segments are propelled by increasing public interest in genetic health, advancements in technology, and greater accessibility to genetic testing services. Together, they highlight the evolving landscape of genetic testing that prioritizes individual health insights and informed decision-making. ## Competitive Benchmarking The human genetics market is currently characterized by a dynamic competitive landscape, driven by rapid advancements in technology and increasing demand for personalized medicine. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Roche (CH) are at the forefront, leveraging their extensive research capabilities and innovative product offerings. Illumina (US) focuses on next-generation sequencing technologies, which are pivotal for genomic research and diagnostics. Meanwhile, Thermo Fisher Scientific (US) emphasizes a broad portfolio that includes reagents and instruments for genetic analysis, positioning itself as a comprehensive solution provider. Roche (CH) is strategically enhancing its diagnostics segment, particularly in oncology, which aligns with the growing trend towards precision medicine. Collectively, these strategies foster a competitive environment that is increasingly centered on innovation and technological advancement.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set industry standards and drive technological advancements that smaller firms often follow. In September Illumina (US) announced a partnership with a leading UK-based research institution to develop a new genomic sequencing platform aimed at improving diagnostic accuracy in rare diseases. This collaboration is strategically significant as it not only enhances Illumina's product offerings but also strengthens its foothold in the UK market, which is increasingly prioritizing genomic research. In October Roche (CH) launched a new liquid biopsy test that detects genetic mutations associated with various cancers. This innovation is crucial as it aligns with the rising demand for non-invasive diagnostic methods, potentially transforming cancer care by enabling earlier detection and personalized treatment plans. Roche's commitment to advancing oncology diagnostics underscores its strategic focus on precision medicine. In August Thermo Fisher Scientific (US) expanded its operations in the UK by opening a new facility dedicated to the production of genetic analysis tools. This move is indicative of the company's strategy to enhance its manufacturing capabilities and meet the growing demand for genetic testing services. By investing in local production, Thermo Fisher aims to reduce lead times and improve service delivery to its clients. As of November the competitive trends in the human genetics market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into genetic research and diagnostics. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing product offerings. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological innovation, reliability in supply chains, and the ability to deliver personalized solutions. This shift suggests that companies that prioritize R&D and strategic partnerships will be better positioned to thrive in this rapidly evolving market. ## Recent News & Developments In recent months, the UK Human Genetics Market has witnessed significant progress, particularly in genomic research and testing. Companies such as Illumina and QIAGEN are leading advancements in next-generation sequencing technologies, contributing to the enhancement of precision medicine in the UK healthcare sector. Recently, in September 2023, Illumina announced an agreement with Genomics England to collaborate on expanding genetic testing capabilities within the National Health Service, which is expected to improve accessibility to genomic diagnostics. Additionally, Regeneron Pharmaceuticals reported new findings in gene therapy that could potentially transform treatments for rare diseases, further illustrating the innovation landscape in the UK. In terms of mergers, in August 2023, Myriad Genetics acquired a portfolio of diagnostic tests from a competing firm, broadening its capabilities in hereditary cancer testing within the UK. In the past few years, significant investments have been made, notably by Oxford Nanopore Technologies, which raised substantial funding in early 2022 to drive product development and market expansion. This flourishing market appears poised for further growth, driven by advancements in genetic research and strategic collaborations among key players. ## Report Scope | MARKET SIZE 2024 | 1589.45(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1761.11(USD Million) | | MARKET SIZE 2035 | 4912.15(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.8% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Agilent Technologies (US), QIAGEN (DE), Myriad Genetics (US), BGI Genomics (CN), Genomatix (DE), Fulgent Genetics (US) | | Segments Covered | Application, Test | | Key Market Opportunities | Advancements in gene editing technologies create new avenues for personalized medicine in the human genetics market. | | Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the human genetics market. | | Countries Covered | UK | ## Frequently Asked Questions **Q: What was the market valuation of the UK human genetics market in 2024?** A: The market valuation of the UK human genetics market was $1589.45 Million in 2024. **Q: What is the projected market valuation for the UK human genetics market by 2035?** A: The projected market valuation for the UK human genetics market is $4912.15 Million by 2035. **Q: What is the expected CAGR for the UK human genetics market during the forecast period 2025 - 2035?** A: The expected CAGR for the UK human genetics market during the forecast period 2025 - 2035 is 10.8%. **Q: Which companies are considered key players in the UK human genetics market?** A: Key players in the UK human genetics market include Illumina, Thermo Fisher Scientific, Roche, Agilent Technologies, QIAGEN, Myriad Genetics, BGI Genomics, Genomatix, and Fulgent Genetics. **Q: What are the main application segments of the UK human genetics market?** A: The main application segments of the UK human genetics market include Wellness & E-Commerce, Preventive Medicine, and Diagnostic & Treatment. **Q: What was the market size for the Diagnostic & Treatment segment in 2024?** A: The market size for the Diagnostic & Treatment segment was $689.45 Million in 2024. **Q: What is the projected market size for the Preventive Medicine segment by 2035?** A: The projected market size for the Preventive Medicine segment is $1800.0 Million by 2035. **Q: Which testing categories are included in the UK human genetics market?** A: Testing categories in the UK human genetics market include NIPT, Carrier Testing, Pharmacogenomic Testing, Karyotype Testing, Thrombophilia Testing, Septin 9 Biomarker Testing, NGS, and Others. **Q: What was the market size for NGS testing in 2024?** A: The market size for NGS testing was $500.0 Million in 2024. **Q: What is the projected market size for Carrier Testing by 2035?** A: The projected market size for Carrier Testing is $750.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-human-genetics-market-49310*